Adverse events secondary to cetuximab therapy in head & neck cancer therapy and risk factors for serious outcomes - Stanbouly, D; Philipone, E; Morlandt, A B; Kaleem, A; Chuang, S K; Patel, N (Oral Oncol, 2022)